Vertex Pharmaceuticals (VRTX)
NASDAQ: VRTX
· Real-Time Price · USD
385.74
3.87 (1.01%)
At close: Sep 26, 2025, 3:59 PM
380.00
-1.49%
After-hours: Sep 26, 2025, 07:56 PM EDT
Vertex Pharmaceuticals Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALYFTREK Revenue | 156.8M | 53.9M | 594.6M | 186.9M | 2.45B | 2.48B | 2.33B | 2.27B | 2.24B | 2.1B | 2.02B | 2.01B | 1.89B | 1.76B | 1.69B | 1.56B | 1.26B | 1.19B | 1.09B | 960.31M | 917.72M | 895.23M | 420.11M |
| ALYFTREK Revenue Growth | +190.91% | -90.94% | +218.14% | -92.37% | -1.39% | +6.44% | +2.59% | +1.51% | +6.85% | +3.72% | +0.55% | +6.20% | +7.47% | +4.08% | +8.79% | +23.91% | +5.23% | +9.41% | +13.56% | +4.64% | +2.51% | +113.10% | n/a |
| Manufactured Product, Other Revenue | 236.1M | 170.8M | 2.72B | 2.58B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Manufactured Product, Other Revenue Growth | +38.23% | -93.72% | +5.25% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TRIKAFTA-KAFTRIO Revenue | 2.55B | 2.54B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TRIKAFTA-KAFTRIO Revenue Growth | +0.62% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 910.9M | 826.6M | 832M | 847.7M | 806.8M | 967.4M | 735.3M | 766.5M | 800M | 807.2M | 687.2M | 730.5M | 655.5M | 632.3M | 590.2M | 518.83M | 458.91M | 404.97M | 360.02M | 251.37M | 257.68M | 257.39M | 352.97M | 184.84M | 180.2M | 167.75M | 142.49M | 132.88M | 135.91M | 131.9M |
| Europe Revenue Growth | +10.20% | -0.65% | -1.85% | +5.07% | -16.60% | +31.57% | -4.07% | -4.19% | -0.89% | +17.46% | -5.93% | +11.44% | +3.67% | +7.13% | +13.76% | +13.06% | +13.32% | +12.48% | +43.23% | -2.45% | +0.11% | -27.08% | +90.95% | +2.58% | +7.42% | +17.72% | +7.24% | -2.24% | +3.05% | n/a |
| United States Revenue | 1.83B | 1.65B | 1.84B | 210.7M | 224.5M | 203.3M | 1.57B | 162.8M | 185.4M | 163.8M | 1.46B | 148.2M | 125.6M | 97M | 1.39B | 82.45M | 77.54M | 64.9M | 1.21B | 62.34M | 56.49M | 70.13M | 1.01B | 710.32M | 700.62M | 641.1M | 677.12M | 620.49M | 584.81M | 482.67M |
| United States Revenue Growth | +10.52% | -10.00% | +771.95% | -6.15% | +10.43% | -87.09% | +867.20% | -12.19% | +13.19% | -88.78% | +885.43% | +17.99% | +29.48% | -93.04% | +1590.87% | +6.32% | +19.48% | -94.62% | +1835.86% | +10.36% | -19.45% | -93.06% | +42.26% | +1.39% | +9.28% | -5.32% | +9.13% | +6.10% | +21.16% | n/a |
| Other, Non U.S. Revenue | 205.6M | 280.1M | 242.8M | 1.71B | 1.61B | 1.52B | 207.8M | 1.55B | 1.51B | 1.4B | 155.1M | 1.46B | 1.42B | 1.37B | 88.31M | 1.38B | 1.26B | 1.25B | 60.94M | 1.22B | 1.21B | 1.19B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other, Non U.S. Revenue Growth | -26.60% | +15.36% | -85.83% | +6.15% | +6.21% | +631.42% | -86.63% | +3.08% | +7.41% | +805.09% | -89.34% | +2.86% | +3.43% | +1449.37% | -93.61% | +10.02% | +0.28% | +1956.76% | -95.02% | +1.18% | +1.91% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 424.6M | 396.4M | 377.6M | 371.8M | 372.2M | 342.7M | 369.1M | 263.8M | 262.6M | 241.1M | 267.4M | 246.8M | 215.3M | 215.2M | 255.2M | 198.19M | 194.6M | 192.08M | 211.84M | 184.55M | 191.8M | 182.26M | 195.28M | 159.67M | 156.5M | 147.04M | 153.21M | 137.29M | 137.3M | 129.81M | 134.79M | 120.71M | 127.25M | 113.33M | 109.91M | 106.06M | 111.65M | 105.21M | 97.05M | 99.77M | 94.39M | 85.86M |
| Selling, General, and Administrative Revenue Growth | +7.11% | +4.98% | +1.56% | -0.11% | +8.61% | -7.15% | +39.92% | +0.46% | +8.92% | -9.84% | +8.35% | +14.63% | +0.05% | -15.67% | +28.77% | +1.84% | +1.31% | -9.33% | +14.79% | -3.78% | +5.24% | -6.67% | +22.30% | +2.03% | +6.43% | -4.02% | +11.59% | -0.01% | +5.77% | -3.70% | +11.67% | -5.14% | +12.29% | +3.11% | +3.63% | -5.01% | +6.12% | +8.41% | -2.72% | +5.70% | +9.94% | n/a |
| Research and Development Revenue | 978.4M | 979.7M | 998.7M | 875.9M | 5.42B | 865.9M | 1.35B | 861.7M | 896.2M | 742.6M | 694.1M | 645M | 600.1M | 603.1M | 694.3M | 493.75M | 1.41B | 455.97M | 466.58M | 493.5M | 420.93M | 448.53M | 480.01M | 555.95M | 379.09M | 339.49M | 437.88M | 330.51M | 337.53M | 310.55M | 306.66M | 454.95M | 289.45M | 273.56M | 248.45M | 275.37M | 271.01M | 255.86M | 310.43M | 246.28M | 223.86M | 215.6M |
| Research and Development Revenue Growth | -0.13% | -1.90% | +14.02% | -83.83% | +525.44% | -35.94% | +56.86% | -3.85% | +20.68% | +6.99% | +7.61% | +7.48% | -0.50% | -13.14% | +40.62% | -64.91% | +208.59% | -2.27% | -5.45% | +17.24% | -6.15% | -6.56% | -13.66% | +46.65% | +11.66% | -22.47% | +32.49% | -2.08% | +8.69% | +1.27% | -32.59% | +57.18% | +5.81% | +10.11% | -9.78% | +1.61% | +5.92% | -17.58% | +26.05% | +10.02% | +3.83% | n/a |